Spots Global Cancer Trial Database for diffuse large cell lymphoma
Every month we try and update this database with for diffuse large cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Treatment for Advanced B-Cell Lymphoma | NCT01859819 | Diffuse Large C... Burkitt's Lymph... High Grade B-ce... | Rituximab IT Cytarabine | 3 Years - 31 Years | New York Medical College | |
| ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma | NCT00144807 | Diffuse Large C... | rituximab doxorubicin cyclophosphamid... autologous stem... | 18 Years - 59 Years | Lymphoma Study Association | |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | NCT02819583 | Acute Lymphocyt... Chronic Lymphoc... Follicular Lymp... Mantle Cell Lym... B-cell Prolymph... Diffuse Large C... | PCAR-019 (anti-... | 18 Years - | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma | NCT00140660 | Diffuse Large C... | rituximab | 18 Years - 65 Years | Lymphoma Study Association | |
| Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | NCT00376519 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo... | cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra... | 18 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | NCT00602693 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | umbilical cord ... Allopurinol fludarabine pho... Cyclophosphamid... Total body irra... Treg infusion Sirolimus | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients | NCT00949741 | Diffuse Large C... Lymphoblastic L... Burkitt's Lymph... | 18 Years - | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | ||
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | NCT02851589 | Acute Lymphocyt... Chronic Lymphoc... Follicular Lymp... Mantle Cell Lym... B-cell Prolymph... Diffuse Large C... | PCAR-019 (anti-... | 14 Years - | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | NCT01101581 | Non Hodgkin's L... NHL Aggressive NHL Diffuse Large B... | Veltuzumab and ... 90Y-epratuzumab... veltuzumab | 18 Years - | Gilead Sciences | |
| Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation | NCT00591630 | Diffuse Large C... Lymphoma | Zevalin Carmustine Etoposide Cytarabine Melphalan Rituximab Stem Cell Trans... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | NCT02819583 | Acute Lymphocyt... Chronic Lymphoc... Follicular Lymp... Mantle Cell Lym... B-cell Prolymph... Diffuse Large C... | PCAR-019 (anti-... | 18 Years - | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| AMG 319 Lymphoid Malignancy FIH | NCT01300026 | Cancer Chronic Lymphoc... Diffuse Large C... Hematologic Mal... Hematology Leukemia Low Grade Lymph... Lymphoma Mantle Cell Lym... Non-Hodgkin's L... Oncology Oncology Patien... T Cell Lymphoma Tumors | AMG 319 | 18 Years - | Amgen | |
| Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma | NCT00596804 | Non-Hodgkin's L... Lymphoma, Diffu... Lymphoma, Diffu... | veltuzumab | 18 Years - | Gilead Sciences | |
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | NCT01101581 | Non Hodgkin's L... NHL Aggressive NHL Diffuse Large B... | Veltuzumab and ... 90Y-epratuzumab... veltuzumab | 18 Years - | Gilead Sciences | |
| Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) | NCT00598624 | Leukemia Chronic Myeloid... Myelodysplastic... Diffuse Large C... Hodgkin Lymphom... Chronic Lymphoc... Multiple Myelom... | Treosulfan IV | 18 Years - 69 Years | IRCCS San Raffaele | |
| Study of Repeat Intranodal Injections of Ad-ISF35 | NCT00942409 | Non-Hodgkin's L... Follicular Lymp... Diffuse Large C... Mantle Cell Lym... Small Lymphocyt... Chronic Lymphoc... | ISF35 | 18 Years - | University of California, San Diego | |
| Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | NCT00791011 | Hodgkin's Lymph... Low Grade Lymph... Lymphoma Mantle Cell Lym... Non-Hodgkin's L... Diffuse Large C... | AMG 655 Vorinostat Bortezomib | 18 Years - | Amgen | |
| Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | NCT01943682 | Acute Myeloid L... Acute Lymphobla... Burkitt Lymphom... Diffuse Large C... Gray Zone Lymph... Lymphoblastic L... Anaplastic Larg... Hodgkin Lymphom... | CPX-351 | 12 Months - 30 Years | Children's Hospital Medical Center, Cincinnati | |
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | NCT01101581 | Non Hodgkin's L... NHL Aggressive NHL Diffuse Large B... | Veltuzumab and ... 90Y-epratuzumab... veltuzumab | 18 Years - | Gilead Sciences | |
| Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies | NCT00275431 | Follicular Lymp... Diffuse Large C... Mantle Cell Lym... Small Lymphocyt... Chronic Lymphoc... | AT-101 | 18 Years - | Ascenta Therapeutics | |
| Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | NCT05389423 | Diffuse Large C... Non-Hodgkin Lym... Burkitt Lymphom... Plasmablastic L... B-Cell Neoplasm | Vincristine Prednisone Doxorubicin Etoposide Pomalidomide Cyclophosphamid... Rituximab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma | NCT00511043 | Lymphoma, Large... | PTK787 | 18 Years - | Duke University | |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | NCT02851589 | Acute Lymphocyt... Chronic Lymphoc... Follicular Lymp... Mantle Cell Lym... B-cell Prolymph... Diffuse Large C... | PCAR-019 (anti-... | 14 Years - | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma | NCT00596804 | Non-Hodgkin's L... Lymphoma, Diffu... Lymphoma, Diffu... | veltuzumab | 18 Years - | Gilead Sciences | |
| Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors | NCT00001301 | Lymphoma, Non-H... | - | National Institutes of Health Clinical Center (CC) | ||
| Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | NCT00376519 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo... | cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra... | 18 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy | NCT02374333 | Acute Lymphocyt... Diffuse Large C... | huCART19 | 1 Year - 24 Years | University of Pennsylvania | |
| AMG 319 Lymphoid Malignancy FIH | NCT01300026 | Cancer Chronic Lymphoc... Diffuse Large C... Hematologic Mal... Hematology Leukemia Low Grade Lymph... Lymphoma Mantle Cell Lym... Non-Hodgkin's L... Oncology Oncology Patien... T Cell Lymphoma Tumors | AMG 319 | 18 Years - | Amgen | |
| Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | NCT00791011 | Hodgkin's Lymph... Low Grade Lymph... Lymphoma Mantle Cell Lym... Non-Hodgkin's L... Diffuse Large C... | AMG 655 Vorinostat Bortezomib | 18 Years - | Amgen | |
| PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma | NCT00511043 | Lymphoma, Large... | PTK787 | 18 Years - | Duke University | |
| Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma | NCT00596804 | Non-Hodgkin's L... Lymphoma, Diffu... Lymphoma, Diffu... | veltuzumab | 18 Years - | Gilead Sciences | |
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | NCT01101581 | Non Hodgkin's L... NHL Aggressive NHL Diffuse Large B... | Veltuzumab and ... 90Y-epratuzumab... veltuzumab | 18 Years - | Gilead Sciences | |
| Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma | NCT00596804 | Non-Hodgkin's L... Lymphoma, Diffu... Lymphoma, Diffu... | veltuzumab | 18 Years - | Gilead Sciences |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
